Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose colchicine effects on crystal-induced monocyte and neutrophil inflammation in chronic coronary artery disease
NL-OMON49134Phase 3Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of colchicine in coronary arteriosclerosis (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Change in inflammatory cytokine release from monocytes and neutrophils after MSU crystal stimulation. Started Jan 2021; status: active, not recruiting.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON49134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49134.